Grifols, S.A.(GRFS)Earnings, Financials & Key Ratios

GRFS•NASDAQ

$8.41

$7.11B mkt cap·12.6× P/E·Price updated May 6, 2026

SectorHealthcare IndustryLarge Pharma Sub-IndustryVaccines and plasma-derived therapies

AboutGrifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuumfrom prevention, screening, diagnosis, and prognosis to disease and treatment monitoringto serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.Show more

Revenue$7.23B+0.2%
EBITDA$1.62B-0.6%
Net Income$386M+146.1%
EPS (Diluted)0.57+147.8%
Gross Margin35.7%-7.9%
EBITDA Margin22.41%-0.8%
Operating Margin16.43%-0.6%
Net Margin5.34%+145.6%
ROE4.77%+144.8%
ROIC5.36%+7.0%
Debt/Equity1.15-1.9%
Interest Coverage1.98+46.1%

Technical→

GRFS Key Insights

Grifols, S.A. (GRFS) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Healthy dividend yield of 2.5%
✓Trading at only 0.6x book value

✗Weaknesses

✗Weak 3Y average ROE of 2.4%

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

GRFS Price & Volume

Grifols, S.A. (GRFS) stock price & volume — 10-year historical chart

Loading chart...

GRFS Growth Metrics

Grifols, S.A. (GRFS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years6.27%

5 Years6.24%

3 Years6.02%

TTM4.06%

Profit CAGR

10 Years-3.16%

5 Years-8.99%

3 Years27.79%

TTM155.6%

EPS CAGR

10 Years-3.09%

5 Years-4.83%

3 Years22.51%

TTM159.86%

Return on Capital

10 Years7.1%

5 Years5.06%

3 Years5.61%

Last Year6.42%

GRFS Recent Earnings

Grifols, S.A. (GRFS) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 1/12 qtrs (8%)●Beat Revenue 7/12 qtrs (58%)

Q1 2026Latest

Feb 26, 2026

EPS

$0.29

Est $0.29

-0.3%

Revenue

$2.3B

Est $2.3B

-0.2%

Q1 2026

Feb 25, 2026

EPS

$0.29

Est $0.29

-0.3%

Revenue

$2.3B

Est $2.3B

-0.2%

Q4 2025

Nov 4, 2025

EPS

$0.22

Est $0.24

-9.6%

Revenue

$2.2B

Est $2.2B

+1.5%

Q3 2025

Jul 28, 2025

EPS

$0.19

Est $0.23

-17.4%

Revenue

$2.2B

Est $1.9B

+19.8%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 26, 2026	$0.29vs $0.29-0.3%	$2.3Bvs $2.3B-0.2%
Q1 2026	Feb 25, 2026	$0.29vs $0.29-0.3%	$2.3Bvs $2.3B-0.2%
Q4 2025	Nov 4, 2025	$0.22vs $0.24-9.6%	$2.2Bvs $2.2B+1.5%
Q3 2025	Jul 28, 2025	$0.19vs $0.23-17.4%	$2.2Bvs $1.9B+19.8%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
TAKTakeda Pharmaceutical Company LimitedDirect Competitor	52.82B	16.72	77.66	7.45%	2.56%	1.5%	0.65
CSLCarlisle Companies IncorporatedDirect Competitor	15.29B	373.96	21.84	0.33%	14.57%	34.48%	1.60
BHVNBiohaven Ltd.Direct Competitor	1.06B	10.04	-1.46			-8.66%	5.36
OCSLOaktree Specialty Lending CorporationDirect Competitor	1.1B	12.51	32.08	60.93%		3.45%	1.01
BCRXBioCryst Pharmaceuticals, Inc.Product Competitor	1.85B	8.83	7.30	94.1%	-51.71%
RAREUltragenyx Pharmaceutical Inc.Product Competitor	2.55B	25.93	-4.45	20.13%	-91.03%	-6.08%
AKROAkero Therapeutics, Inc.Product Competitor	4.5B	54.65	-14.57			-30.58%	0.05
ALNYAlnylam Pharmaceuticals, Inc.Product Competitor	40.43B	303.00	130.04	65.19%	13.46%	98.29%	1.62

Compare GRFS vs Peers

Grifols, S.A. (GRFS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs TAK

Most directly comparable listed peer for GRFS.

Scale Benchmark

vs AMGN

Larger-name benchmark to compare GRFS against a more recognizable public peer.

Peer Set

Compare Top 5

vs TAK, CSL, BHVN, OCSL

GRFS Income Statement

Grifols, S.A. (GRFS) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	4.32B	4.49B	5.1B	5.34B	4.93B	6.06B	6.59B	7.21B	7.23B
Revenue Growth %	6.62%	3.91%	13.64%	4.73%	-7.62%	22.92%	8.71%	9.41%	0.2%
Cost of Goods Sold	2.17B	2.44B	2.76B	3.08B	2.97B	3.85B	4.11B	4.42B	4.65B
COGS % of Revenue	50.16%	54.32%	54.08%	57.77%	60.22%	63.49%	62.33%	61.25%	64.3%
Gross Profit	2.15B▲ 0%	2.05B▼ 4.8%	2.34B▲ 14.2%	2.26B▼ 3.7%	1.96B▼ 13.0%	2.21B▲ 12.8%	2.48B▲ 12.2%	2.79B▲ 12.5%	2.58B▼ 7.7%
Gross Margin %	49.84%	45.68%	45.92%	42.23%	39.78%	36.51%	37.67%	38.75%	35.7%
Gross Profit Growth %	12.54%	-4.76%	14.23%	-3.68%	-12.97%	12.8%	12.19%	12.53%	-7.68%
Operating Expenses	1.15B	1.06B	1.21B	1.26B	1.37B	1.43B	1.7B	1.6B	1.39B
OpEx % of Revenue	26.6%	23.52%	23.73%	23.58%	27.72%	23.6%	25.81%	22.22%	19.27%
Selling, General & Admin	860.35M	814.77M	942.82M	985.62M	1.06B	1.11B	1.27B	1.14B	1.02B
SG&A % of Revenue	19.92%	18.16%	18.49%	18.46%	21.52%	18.27%	19.2%	15.86%	14.13%
Research & Development	288.32M	240.66M	276.02M	294.22M	354.88M	361.14M	395.28M	384.04M	358.28M
R&D % of Revenue	6.68%	5.36%	5.41%	5.51%	7.19%	5.96%	6%	5.32%	4.96%
Other Operating Expenses	0	0	-8.97M	-20.8M	-48.86M	-37.66M	40.36M	74.48M	13.45M
Operating Income	1B▲ 0%	994.12M▼ 0.9%	1.13B▲ 13.8%	996.13M▼ 12.0%	595.06M▼ 40.3%	782.44M▲ 31.5%	782.32M▼ 0.0%	1.19B▲ 52.4%	1.19B▼ 0.4%
Operating Margin %	23.24%	22.16%	22.19%	18.65%	12.06%	12.9%	11.87%	16.53%	16.43%
Operating Income Growth %	6.81%	-0.92%	13.81%	-11.95%	-40.26%	31.49%	-0.02%	52.37%	-0.4%
EBITDA	1.22B	1.22B	1.43B	1.32B	954.83M	1.19B	1.23B	1.63B	1.62B
EBITDA Margin %	28.23%	27.25%	28.12%	24.68%	19.36%	19.68%	18.64%	22.6%	22.41%
EBITDA Growth %	6.8%	0.32%	17.26%	-8.1%	-27.54%	24.99%	2.96%	32.65%	-0.64%
D&A (Non-Cash Add-back)	215.49M	228.61M	302.45M	321.53M	359.77M	410.98M	446.42M	437.9M	432.24M
EBIT	945.25M	1B	1.14B	1.1B	584.27M	782.56M	723.08M	1.05B	1.19B
Net Interest Income	-253.67M	-279.28M	-228.77M	-275.44M	-222.26M	-410.68M	-453.63M	-725.1M	-567.67M
Interest Income	9.68M	13.99M	114.2M	9.14M	11.55M	33.86M	62.43M	48.05M	32.66M
Interest Expense	249.53M	274.16M	324.38M	284.58M	233.81M	444.54M	516.06M	773.15M	600.33M
Other Income/Expense	-307.62M	-268.28M	-314.26M	-117.5M	-244.61M	-444.42M	-575.3M	-748.02M	-596.49M
Pretax Income	695.72M▲ 0%	725.84M▲ 4.3%	817.1M▲ 12.6%	878.63M▲ 7.5%	350.45M▼ 60.1%	338.01M▼ 3.5%	207.02M▼ 38.8%	444M▲ 114.5%	590.73M▲ 33.0%
Pretax Margin %	16.11%	16.18%	16.03%	16.45%	7.1%	5.57%	3.14%	6.16%	8.17%
Income Tax	34.41M	131.44M	168.46M	169.64M	85.13M	90.11M	43.35M	231.19M	110.46M
Effective Tax Rate %	4.95%	18.11%	20.62%	19.31%	24.29%	26.66%	20.94%	52.07%	18.7%
Net Income	662.7M▲ 0%	596.64M▼ 10.0%	625.15M▲ 4.8%	618.55M▼ 1.1%	188.73M▼ 69.5%	185.03M▼ 2.0%	42.32M▼ 77.1%	156.92M▲ 270.8%	386.13M▲ 146.1%
Net Margin %	15.35%	13.3%	12.26%	11.58%	3.83%	3.05%	0.64%	2.18%	5.34%
Net Income Growth %	21.49%	-9.97%	4.78%	-1.06%	-69.49%	-1.96%	-77.13%	270.81%	146.07%
Net Income (Continuing)	661.31M	594.41M	648.64M	708.99M	265.33M	247.9M	163.67M	212.81M	480.27M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	4.89M	471.05M	2.27B	1.61B	1.79B	2.33B	2.15B	2.72B	2.33B
EPS (Diluted)	0.97▲ 0%	0.87▼ 10.3%	0.94▲ 8.0%	0.73▼ 22.3%	0.27▼ 63.0%	0.31▲ 14.8%	0.09▼ 71.0%	0.23▲ 155.6%	0.57▲ 147.8%
EPS Growth %	21.25%	-10.31%	8.05%	-22.34%	-63.01%	14.81%	-70.97%	155.56%	147.83%
EPS (Basic)	0.97	0.87	0.95	0.73	0.27	0.31	0.09	0.23	0.57
Diluted Shares Outstanding	684.24M	684.71M	663.69M	685.52M	681.56M	679.81M	679.76M	680.02M	680.58M
Basic Shares Outstanding	684.2M	684.71M	659.98M	685.52M	681.56M	679.81M	679.76M	680.02M	680.58M
Dividend Payout Ratio	32.93%	46.74%	38.19%	18.31%	133.76%	0.32%	-	0.61%	31.84%

GRFS Balance Sheet

Grifols, S.A. (GRFS) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	2.95B	3.48B	6.02B	3.16B	5.51B	4.69B	6.13B	5.73B	5.07B
Cash & Short-Term Investments	886.52M	1.03B	2.76B	590.51M	2.69B	580.24M	646.04M	1B	824.65M
Cash Only	886.52M	1.03B	832.87M	579.65M	655.49M	549.21M	529.58M	979.78M	824.65M
Short-Term Investments	0	0	1.93B	10.86M	2.03B	31.03M	116.47M	21.18M	0
Accounts Receivable	385.26M	401.57M	528.13M	383.23M	434.14M	774.2M	692.86M	1.08B	844.64M
Days Sales Outstanding	32.57	32.67	37.81	26.19	32.12	46.6	38.36	54.62	42.66
Inventory	1.63B	1.95B	2.63B	2B	2.26B	3.24B	3.48B	3.56B	3.29B
Days Inventory Outstanding	274.55	291.94	348.07	236.91	277.62	306.77	309.38	294.13	258.77
Other Current Assets	33.06M	63.1M	78.03M	172.88M	131.63M	80.88M	1.31B	78.58M	100.96M
Total Non-Current Assets	7.97B	8.99B	11.43B	12.11B	13.72B	16.54B	14.86B	15.68B	14.68B
Property, Plant & Equipment	1.76B	1.95B	3.21B	3B	3.34B	4.28B	4.19B	4.31B	4.05B
Fixed Asset Turnover	2.45x	2.30x	1.59x	1.78x	1.48x	1.42x	1.57x	1.67x	1.78x
Goodwill	4.59B	5.21B	6.18B	5.33B	6.23B	7.01B	6.8B	7.4B	6.83B
Intangible Assets	1.27B	1.39B	1.61B	1.56B	1B	2.95B	1.21B	2.93B	2.73B
Long-Term Investments	259.06M	228.82M	278.35M	2.07B	2.27B	1.99B	451.9M	528.97M	592.75M
Other Non-Current Assets	29.84M	105.69M	6.1M	0	882.61M	124.19M	2.21B	167.72M	15.99M
Total Assets	10.92B▲ 0%	12.48B▲ 14.3%	17.45B▲ 39.8%	15.27B▼ 12.4%	19.23B▲ 25.9%	21.23B▲ 10.4%	20.99B▼ 1.1%	21.41B▲ 2.0%	19.75B▼ 7.7%
Asset Turnover	0.40x	0.36x	0.29x	0.35x	0.26x	0.29x	0.31x	0.34x	0.37x
Asset Growth %	7.8%	14.26%	39.83%	-12.45%	25.92%	10.38%	-1.12%	1.97%	-7.73%
Total Current Liabilities	977.99M	1.26B	1.53B	1.34B	3.47B	2.02B	2.33B	2.16B	2.02B
Accounts Payable	423.1M	561.88M	653.16M	601.62M	628.99M	787.96M	822.95M	852.3M	840.64M
Days Payables Outstanding	71.3	84.15	86.46	71.18	77.29	74.7	73.11	70.42	66.03
Short-Term Debt	129.12M	7.08M	358.69M	276.93M	2.35B	578.92M	916.51M	523.13M	385.84M
Deferred Revenue (Current)	14.23M	15.53M	24.1M	23.98M	0	37.83M	0	70.86M	76.97M
Other Current Liabilities	275.65M	507.75M	294.78M	264.51M	119.44M	381.59M	108.6M	81.95M	459.8M
Current Ratio	3.01x	2.77x	3.92x	2.37x	1.59x	2.32x	2.64x	2.66x	2.51x
Quick Ratio	1.35x	1.22x	2.21x	0.87x	0.94x	0.72x	1.14x	1.01x	0.88x
Cash Conversion Cycle	235.82	240.46	299.42	191.92	232.45	278.67	274.63	278.34	235.4
Total Non-Current Liabilities	6.31B	6.52B	8.22B	7.22B	8.44B	11.23B	11.15B	10.64B	10.12B
Long-Term Debt	5.87B	6.01B	6.84B	5.9B	6.94B	8.15B	8.99B	8.42B	7.39B
Capital Lease Obligations	5.42M	9.54M	781.58M	690.86M	825.16M	914.59M	1B	1.02B	968.59M
Deferred Tax Liabilities	388.91M	404.4M	520.65M	556.81M	0	1.03B	0	1.01B	906.61M
Other Non-Current Liabilities	29.4M	86.37M	77.45M	53.93M	675.34M	1.12B	1.16B	170.46M	854.64M
Total Liabilities	7.29B	7.78B	9.75B	8.55B	11.92B	13.25B	13.48B	12.8B	12.13B
Total Debt	6.01B	6.03B	7.98B	6.91B	10.17B	9.75B	11.02B	10.09B	8.74B
Net Debt	5.12B	5B	7.14B	6.33B	9.51B	9.2B	10.49B	9.11B	7.92B
Debt / Equity	1.65x	1.28x	1.04x	1.03x	1.39x	1.22x	1.47x	1.17x	1.15x
Debt / EBITDA	4.93x	4.93x	5.56x	5.25x	10.65x	8.17x	8.97x	6.19x	5.40x
Net Debt / EBITDA	4.20x	4.09x	4.98x	4.81x	9.96x	7.71x	8.53x	5.59x	4.89x
Interest Coverage	3.79x	3.65x	3.52x	3.87x	2.50x	1.76x	1.40x	1.35x	1.98x
Total Equity	3.63B▲ 0%	4.7B▲ 29.2%	7.68B▲ 63.6%	6.72B▼ 12.5%	7.32B▲ 8.9%	7.98B▲ 9.0%	7.51B▼ 5.8%	8.61B▲ 14.6%	7.6B▼ 11.7%
Equity Growth %	-2.52%	29.24%	63.62%	-12.55%	8.88%	9.01%	-5.8%	14.55%	-11.7%
Book Value per Share	5.31	6.86	11.58	9.80	10.74	11.73	11.05	12.66	11.17
Total Shareholders' Equity	3.63B	4.23B	5.41B	5.11B	5.52B	5.65B	5.37B	5.88B	5.27B
Common Stock	1.03B	1.03B	134.26M	119.6M	119.6M	119.6M	119.6M	119.6M	119.95M
Retained Earnings	539.71M	459.89M	0	618.55M	248M	0	79.36M	156.92M	0
Treasury Stock	-62.42M	-55.44M	-55.66M	-43.73M	-164.19M	-162.22M	-152.75M	-134.45M	-130.94M
Accumulated OCI	2.12B	2.79B	4.31B	3.5B	4.41B	4.78B	4.41B	4.83B	4.37B
Minority Interest	4.89M	471.05M	2.27B	1.61B	1.79B	2.33B	2.15B	2.72B	2.33B

GRFS Cash Flow Statement

Grifols, S.A. (GRFS) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	841.75M	737.43M	568.93M	1.11B	596.98M	-10.87M	218.69M	902.17M	1.01B
Operating CF Margin %	19.49%	16.44%	11.16%	20.79%	12.1%	-0.18%	3.32%	12.51%	13.92%
Operating CF Growth %	52.14%	-12.39%	-22.85%	95.16%	-46.23%	-101.82%	2112.42%	312.53%	11.47%
Net Income	695.72M	725.84M	817.1M	618.55M	188.73M	361.26M	207.02M	444M	386.13M
Depreciation & Amortization	215.49M	228.61M	302.45M	321.53M	359.77M	407.86M	446.42M	437.9M	432.24M
Stock-Based Compensation	0	0	0	0	0	0	0	0	0
Deferred Taxes	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	-3.67M	-104.38M	-69.09M	61.66M	229.84M	-170.77M	-71.91M	-2.1M	211.32M
Working Capital Changes	-65.8M	-112.64M	-481.54M	108.6M	-181.35M	-609.22M	-362.84M	22.38M	-24.01M
Change in Receivables	80.11M	-13.14M	-99.37M	-35.43M	-16.81M	-80.17M	-68.81M	-41.88M	-30.74M
Change in Inventory	-165.51M	-231.67M	-323.75M	164.63M	-157.47M	-600.25M	-411.44M	25.82M	-93.17M
Change in Payables	22.29M	135.26M	0	0	0	80.21M	0	0	90.29M
Cash from Investing	-2.19B	-781.87M	-548.79M	-858.12M	-854.15M	-1.98B	-394.72M	886.67M	-556.15M
Capital Expenditures	-322.97M	-307.72M	-310.38M	-280.15M	-247.37M	-375.56M	-224.44M	-232.54M	-406.31M
CapEx % of Revenue	7.48%	6.86%	6.09%	5.25%	5.01%	6.19%	3.4%	3.22%	5.62%
Acquisitions	-1.86B	-524.08M	-119.75M	-468.59M	-519.13M	-1.44B	-29.47M	-285.87M	-99.9M
Investments	-	-	-	-	-	-	-	-	-
Other Investing	762K	550K	-99.21M	-109.37M	-87.65M	3.28M	-62.63M	1.45B	0
Cash from Financing	1.43B	152.5M	-332.36M	-354.4M	2.3B	-173.49M	171.49M	-1.36B	-508.12M
Debt Issued (Net)	1.81B	37.42M	-73.78M	-243.37M	2.75B	-104.29M	-116.39M	-111.49M	-182.5M
Equity Issued (Net)	0	0	0	0	-125.7M	-3.46M	0	0	-123.91M
Dividends Paid	-218.26M	-278.84M	-238.74M	-113.23M	-252.44M	-592K	0	-962K	-122.95M
Share Repurchases	0	0	0	0	-125.7M	-3.46M	0	0	-123.91M
Other Financing	-156.45M	390.87M	-19.83M	2.2M	-70.56M	-65.16M	287.89M	-1.25B	-78.76M
Net Change in Cash	-8.49M▲ 0%	147.27M▲ 1835.0%	-291.81M▼ 298.1%	-162.34M▲ 44.4%	2.1B▲ 1391.1%	-2.13B▼ 201.5%	-19.63M▲ 99.1%	450.2M▲ 2393.4%	-38.85M▼ 108.6%
Free Cash Flow	518.77M▲ 0%	429.71M▼ 17.2%	156.63M▼ 63.5%	830.18M▲ 430.0%	349.6M▼ 57.9%	-386.43M▼ 210.5%	-91.63M▲ 76.3%	530.8M▲ 679.3%	751.14M▲ 41.5%
FCF Margin %	12.01%	9.58%	3.07%	15.55%	7.09%	-6.37%	-1.39%	7.36%	10.39%
FCF Growth %	99.08%	-17.17%	-63.55%	430.03%	-57.89%	-210.53%	76.29%	679.29%	41.51%
FCF per Share	0.76	0.63	0.24	1.21	0.51	-0.57	-0.13	0.78	1.10
FCF Conversion (FCF/Net Income)	1.27x	1.24x	0.91x	1.80x	3.16x	-0.06x	5.17x	5.75x	2.60x
Interest Paid	0	0	0	155.79M	155.12M	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

GRFS Key Ratios

Grifols, S.A. (GRFS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	15.52%	18%	14.32%	10.1%	8.59%	2.69%	2.42%	0.55%	1.95%	4.77%
Return on Invested Capital (ROIC)	9.63%	9.13%	8.08%	6.92%	5.36%	2.99%	3.45%	3.34%	5.01%	5.36%
Gross Margin	47.22%	49.84%	45.68%	45.92%	42.23%	39.78%	36.51%	37.67%	38.75%	35.7%
Net Margin	13.47%	15.35%	13.3%	12.26%	11.58%	3.83%	3.05%	0.64%	2.18%	5.34%
Debt / Equity	1.31x	1.65x	1.28x	1.04x	1.03x	1.39x	1.22x	1.47x	1.17x	1.15x
Interest Coverage	4.12x	3.79x	3.65x	3.52x	3.87x	2.50x	1.76x	1.40x	1.35x	1.98x
FCF Conversion	1.01x	1.27x	1.24x	0.91x	1.80x	3.16x	-0.06x	5.17x	5.75x	2.60x
Revenue Growth	2.93%	6.62%	3.91%	13.64%	4.73%	-7.62%	22.92%	8.71%	9.41%	0.2%

GRFS Frequently Asked Questions

Grifols, S.A. (GRFS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Grifols, S.A. (GRFS) reported $7.51B in revenue for fiscal year 2025. This represents a 1332% increase from $524.3M in 2005.

Grifols, S.A. (GRFS) grew revenue by 0.2% over the past year. Growth has been modest.

Yes, Grifols, S.A. (GRFS) is profitable, generating $401.1M in net income for fiscal year 2025 (5.3% net margin).

Dividend & Returns

Yes, Grifols, S.A. (GRFS) pays a dividend with a yield of 2.52%. This makes it attractive for income-focused investors.

Grifols, S.A. (GRFS) has a return on equity (ROE) of 4.8%. This is below average, suggesting room for improvement.

Grifols, S.A. (GRFS) generated $771.9M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More GRFS

Grifols, S.A. (GRFS) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Grifols, S.A.(GRFS)Earnings, Financials & Key Ratios

GRFS Key Insights

✓Strengths

✗Weaknesses

GRFS Price & Volume

GRFS Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

GRFS Recent Earnings

GRFS Peer Comparison

Compare GRFS vs Peers

vs TAK

vs AMGN

Compare Top 5

GRFS Income Statement

GRFS Balance Sheet

GRFS Cash Flow Statement

GRFS Key Ratios

GRFS Frequently Asked Questions

Explore More GRFS

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation